Skip to main content

About your Search

20130401
20130430
SHOW
STATION
KQED (PBS) 2
KRCB (PBS) 2
WETA 1
WMPT (PBS) 1
LANGUAGE
Search Results 0 to 5 of about 6 (some duplicates have been removed)
PBS
Apr 15, 2013 5:30pm PDT
... when they clamped down on the patents, our labs and all others were shut down. >> brown: kevin noonan, same question to you. as someone involved in the patent world and research, what do you think is the essence of this? >> i think that that is true. you're looking at what is going to enable the technology to get to the most patients the quickest and the most reliably. frankly myriad has done a great job of doing that because there are more people who have gotten this test than i think would have gotten it otherwise more consistently and more reliably than if it had been scattered among hundreds of thousands of individual research labs. >> brown: ellen, address that specifically. that claim has been put out there that scholarly work has hardly been stopped. there's been plenty of research done. i mean studies of the research done on this. >>i think thosof us in the know will tell you that this has had a chilling effect on research and not as much research has been able to be done. one company has had a monopoly on this testing. for companies and laboratories that wanted to find better
PBS
Apr 15, 2013 10:00pm PDT
's a plaintiff in today's case. kevin noonan an intellectual property attorney and founder of the blog patent docs, dot-org. you heard marcia talk about the legal arguments. as someone involved in genetic counseling and research, what's the essence of this case for you? what's at stake? >> well, i've really seen from the ground floor wha thi has ne to patnt caroverhe last 15 years. keep in mind that when these genes were cloned many laboratories were offering this testing. there was nothing novel here, no invention, no special process, no special machine. we were doing this testing in our laboratory at yale. and then when the patents became... when they clamped down on the patents, our labs and all others were shut down. >> brown: kevin noonan, same question to you. as someone involved in the patent world and research, what do you think is the essence of this? >> i think that that is true. you're looking at what is going to enable the technology to get to the most patients the quickest and the most reliably. frankly myriad has done a great job of doing that because there are more people who h
Search Results 0 to 5 of about 6 (some duplicates have been removed)